In the general news, Russia suffered two suicide bomber attacks near Sochi, ahead of the February Olympics. In the U.S., the stock markets ended in bubble-esque fashion, with TWTR having a market cap of $40 B. In the courts, two different federal rulings conflicted over the legality of the NSA spying efforts, setting the stage for the Supreme Curt to rule.
In healthcare business news, Myriad Genetics (MYGN) shares fell when CMS cut reimbursement by 50% for the BRCA breast cancer tests.
On the data front, all was quiet in the house, not a creature was stirring, not even a mouse.
From the FDA, Novo Nordik’s Tretten was approved to treat a are form of hemophilia, known as congenital Factor XIII A-subunit deficiency. Also, Sanofi’s Lemtrada was surprisingly rejected to treat MS. The agency cited poor Phase 3 trial design.